TPCW
TGTX icon

TD Private Client Wealth’s TG Therapeutics TGTX Stock Holding History

TD Private Client Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92K Buy
+35
New +$1.43K ﹤0.01% 1366
2021
Q3 		– Sell
-14
Closed -$543 – 1243
2021
Q2 		$543 Buy
+14
New +$550 ﹤0.01% 1171

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

TD Private Client Wealth's TGTX Position: Q2 2026 in Review

TD Private Client Wealth opened a new position in TG Therapeutics (TGTX) in Q2 2026: 35 shares worth $1.92K. The stake represents ﹤0.01% of the portfolio and ranks #1366 among its holdings. This is a return to the name: TD Private Client Wealth previously reported a position in TGTX as recently as Q2 2021.

TD Private Client Wealth first reported a position in TGTX in Q2 2021 and has held it in 2 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • TD Private Client Wealth held 35 shares of TG Therapeutics worth $1.92K as of Q2 2026.
  • TG Therapeutics was a new TD Private Client Wealth position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1366 holding.
  • TD Private Client Wealth first reported a position in TG Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.